AbbVie

St. Louis Financial Planners Asset Management, LLC initiated a new stake in AbbVie (ABBV -1.04%), acquiring 14,630 shares for an estimated $3.39 million in Q3 2025.

What happened

According to a Securities and Exchange Commission (SEC) filing dated October 02, 2025, St. Louis Financial Planners Asset Management, LLC disclosed a new position in AbbVie(ABBV -1.04%). The firm acquired 14,630 shares, bringing its quarter-end holding to $3.39 million. The position accounted for 2.1842% of the fund’s $155,093,822 in reportable U.S. equity assets across 37 positions.

What else to know

This new position represents 2.2% of the fund’s 13F assets as of 2025-09-30

Top holdings after the filing:

• NYSEMKT:BIL: $36.73 million (23.7% of AUM as of 2025-09-30)
• NYSEMKT:TFLO: $17.27 million (11.1% of AUM as of 2025-09-30)
• NASDAQ:BSCP: $10.45 million (6.7% of AUM as of 2025-09-30)
• NASDAQ:PLTR: $9.23 million (6.0% of AUM as of 2025-09-30)
• NASDAQ:AVGO: $5.16 million (3.3% of AUM as of 2025-09-30)

As of October 1, 2025, AbbVie shares were priced at $244.38, up 24.08% over the past year and outperforming the S&P 500 by 11.71 percentage points

Company Overview

Company Snapshot

AbbVie generates revenue primarily through the development, manufacturing, and sale of branded pharmaceuticals, including key products such as HUMIRA, SKYRIZI, RINVOQ, IMBRUVICA, and BOTOX Therapeutic.

The company operates a research-driven business model, focusing on innovation and the expansion of its drug portfolio across multiple therapeutic areas.

AbbVie serves a global customer base, including healthcare providers, hospitals, and government agencies, with a focus on advanced therapies for autoimmune diseases, oncology, and specialty care.

AbbVie discovers, develops, manufactures, and sells pharmaceuticals worldwide, including products for autoimmune diseases, oncology, and other conditions. Its diversified portfolio and commitment to research support its competitive position in the healthcare sector.

Foolish take

AbbVie is one of the top pharmaceutical companies on the market right now, despite its relatively recent loss of patent for Humira, which was a blockbuster drug for the company. Despite this, its dividend remains strong and its drug pipeline robust. Several new drugs are in the works for fields like immunology, oncology, and aesthetics.

Since its acquisition of Allergan, maker of Botox, AbbVie has been burdened with a higher debt load than usual, but equally high cash flows have kept balance sheets healthy. However, a dependence on a few successful drugs does create serious risk should regulation or pricing pressures become a more significant factor in the near term. Higher interest rates could also become a problem, should the company need to refinance the debt it acquired in 2019 with the purchase of Allergan.

Even so, AbbVie is still a solid Wall Street Buy recommendation, with 5 Strong Buys and 13 Buys for October, as well as 9 Hold recommendations. It continues to beat on analysis estimated EPS this year, showing that it can, in fact, pivot despite the loss of a major income stream.

Glossary

Stake: The ownership or investment a firm holds in a particular company or asset.
Reportable AUM: Assets under management that must be disclosed in regulatory filings, such as the SEC’s 13F report.
13F assets: U.S. equity securities managed by institutional investment managers, reported quarterly to the SEC on Form 13F.
Top holdings: The largest investments in a fund’s portfolio, typically ranked by market value.
Dividend yield: Annual dividends paid by a company as a percentage of its current share price.
Outperforming: Achieving a higher return than a benchmark index or comparable investment.
TTM: The 12-month period ending with the most recent quarterly report.
Branded pharmaceuticals: Prescription drugs sold under a trademarked brand name, as opposed to generic versions.
Autoimmune diseases: Medical conditions where the immune system mistakenly attacks the body’s own tissues.
Oncology: The branch of medicine focused on the diagnosis and treatment of cancer.

The announcement of a new buildout, as well as developments on the political front, were the factors driving up AbbVie (ABBV 5.72%) stock on Wednesday. The pharmaceutical company’s shares rose by nearly 6% in value as a result, during a session when the S&P 500 (^GSPC 0.34%) crept up a comparatively modest 0.3%.

Getting out the shovels

On Tuesday afternoon, AbbVie reported that it had begun construction on a $70 million expansion of its AbbVie Bioresearch Center (ABC) in the Massachusetts city of Worcester. The project is aimed at bolstering both research and development (R&D) of investigational medicines and manufacturing, specifically of biologics.

Image source: Getty Images.

The buildout will see an expansion of existing manufacturing spaces, in addition to the construction of a three-story building to house warehouse, office, and laboratory facilities.

Dovetailing with the Trump administration’s goal of locating more corporate assets such as factories in this country, AbbVie said that this is part of a $10 billion-plus aim to support the advancement of biologics.

The company quoted COO Azita Saleki-Gerhardt as saying that the project will also “build upon its impressive track record of developing, manufacturing, and launching next-generation complex biologic medicines.”

A deal with Trump

AbbVie also benefited from the latest moves of a major peer in the pharmaceutical realm. On Tuesday, Pfizer CEO Albert Bourla formally agreed to lower the prices of a clutch of its drugs, apparently for the Medicaid program. His company will also get a break from the pharmaceutical industry tariffs planned by the Trump administration, as Pfizer has pledged to invest more in the U.S.

If Pfizer can do it, so can AbbVie. It seems the two major threats hanging over the pharmaceutical industry — pricing and tariffs — might not be as scary as they first appeared.